Brazil: Food, Drugs, Healthcare, Life Sciences

The Brazilian Patent and Trademark Office (BRPTO) and Peru's INDECOPI have launched a collaborative examination initiative for patent applications in pharmaceuticals, biotechnology, and natural products. This partnership, formalized through a 2025 Bilateral Cooperation Memorandum, will provide expedited technical examination for qualifying PCT applications that entered the national phase between October 2022 and July 2023.

Brazil's food and drug regulatory agency Anvisa has initiated administrative proceedings to review advertising regulations for medicines and food products, responding to constitutional challenges...

This page appears to be a security verification checkpoint that temporarily blocks access while validating the incoming request. The system implements protective measures to distinguish legitimate users from automated traffic or potential security threats.

The Brazilian Patent and Trademark Office (BRPTO) and Peru's INDECOPI have launched a collaborative examination initiative for patent applications in pharmaceuticals, biotechnology, and natural products. This partnership, formalized through a 2025 Bilateral Cooperation Memorandum, will provide expedited technical examination for qualifying PCT applications that entered the national phase between October 2022 and July 2023.

A morosidade no registro de agroquímicos no Brasil persiste mesmo após ampliação dos prazos legais, levando empresas a recorrerem ao Poder Judiciário para combater a inércia administrativa. O artigo examina como a judicialização tem se tornado estratégia essencial para assegurar a conclusão de análises técnicas em prazo razoável, especialmente diante do backlog significativo no IBAMA.

A Lei nº 15.471/2026 institui a Ensceis, transformando o poder de compra do SUS em instrumento de política industrial para reduzir a dependência produtiva e tecnológica do Brasil em saúde. O KLA preparou um e-book detalhando os principais impactos da nova estratégia nacional, incluindo credenciamento de empresas estratégicas, produtos prioritários e parcerias de transferência de tecnologia.

A Lei nº 15.471/2026 institui a Ensceis, transformando o poder de compra do SUS em instrumento de política industrial para reduzir a dependência produtiva e tecnológica do Brasil em saúde. O KLA preparou um e-book detalhando os principais impactos da nova estratégia nacional, incluindo credenciamento de empresas estratégicas, produtos prioritários e parcerias de transferência de tecnologia.

This page appears to be a security verification checkpoint that temporarily blocks access while validating the incoming request. The system implements protective measures to distinguish legitimate users from automated traffic or potential security threats.

On June 21, 2026, Statute #15,471 was published, resulting from Bill #2,583/20. The new statute established the National Health Strategy for the Health Economic-Industrial Complex (ENSCEIS in the Portuguese acronym). The term “established” is not technically accurate, since, in substance, the strategy had already been created in 2023 by Decree #11,715, which in turn merely consolidated pre-existing programs, such as the Productive Development Partnerships (PDPs) dating back to 2008.